Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-28T04:10:07.268Z Has data issue: false hasContentIssue false
  • English
  • Français

Reconsidering Genetic Antidiscrimination Legislation

Published online by Cambridge University Press:  01 January 2021

Jon Beckwith  and
Joseph S. Alper
Get access Rights & Permissions [Opens in a new window]

Extract

Until approximately twenty years ago, advances in the study of human genetics had little influence on the practice of medicine. In the 1980s, this changed dramatically with the mapping of the altered genes that cause cystic fibrosis (CF) and Huntington disease (HD). In just a few years, these discoveries led to DNA-based tests that enabled clinicians to determine whether prospective parents were carriers of CF or whether an individual carried the Huntington gene and, as a result, would almost certainly develop the disease.

Observers interested in the social and economic implications of genetic technology realized that such genetic tests could be used by insurance companies to predict which insurance applicants were likely to become ill or even die from these diseases.

Type
Article
Information
Journal of Law, Medicine & Ethics , Volume 26 , Issue 3 , Fall 1998 , pp. 205 - 210
Copyright
Copyright © American Society of Law, Medicine and Ethics 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

See Kerem, B., “Identification of the Cystic Fibrosis Gene: Genetic Analysis,” Science, 245 (1989): 1073–80; and Rommens, J.M., “Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping,” Science, 245 (1989): 1059–65.Google Scholar
See Meissen, G.J., “Predictive Testing for Huntington's Disease with Use of a Linked DNA Marker,” N. Engl. J. Med., 318 (1988): 535–42.CrossRefGoogle Scholar
See generally Holtzman, N.A., Proceed with Caution: Predicting Genetic Risks in the Recombinant DNA Era (Baltimore: Johns Hopkins University Press, 1989).Google Scholar
See Gostin, L., “Genetic Discrimination: The Use of Genetically Based Diagnostic and Prognostic Tests by Employers and Insurers,” American Journal of Law & Medicine, XVII (1991): 109–44.CrossRefGoogle Scholar
See Yesley, M.S., “Genetic Privacy, Discrimination, and Social Policy: Challenges and Dilemmas,” Microbial & Comparative Genomics, 2 (1997): 19–35.CrossRefGoogle Scholar
See Billings, P.R., “Discrimination as a Consequence of Genetic Testing,” American Journal of Human Genetics, 50 (1992): 476–82.Google Scholar
See Geller, L.N., “Individual, Family and Societal Dimensions of Genetic Discrimination: A Case Study Analysis,” Science and Engineering Ethics, 2 (1996): 71–88.CrossRefGoogle Scholar
See Lapham, E.V. Kozma, C. Weiss, J.O., “Genetic Discrimination: Perspective of Consumers,” Science, 274 (1996): 621–24.CrossRefGoogle Scholar
See Stolberg, S., “Genetic Bias: Held Hostage by Heredity,” Los Angeles Times, Mar. 27, 1994, at A1, A20; Saltus, R., “Fear of Insurers Leading to Gene Testing in Secret,” Boston Globe, Sept. 12, 1994, at 1, 10; Hilts, P.J., “Panel Reports Genetic Screening Has Cost Some Their Health Plans,” New York Times, Nov. 5, 1993, at A1; and Cherskov, M., “Fighting Genetic Discrimination,” ABA Journal, June (1992): 38.Google Scholar
See Geller, supra note 7.Google Scholar
See Pokorski, R.J., “Insurance Underwriting in the Genetic Era,” American Journal of Human Genetics, 60 (1997): 205–16.Google Scholar
See Billings, supra note 6; and Geller, supra note 7.Google Scholar
See Geller, supra note 7.Google Scholar
See Pokorski, supra note 11.Google Scholar
See Kolata, G., “Advent of Testing for Breast Cancer Leads to Fears of Disclosure and Discrimination,” New York Times, Feb. 4, 1997, at C1, C3.Google Scholar
See Kolata, G., “Genetic Testing Falls Short of Public Embrace,” New York Times, Mar. 27, 1998, at A16; and Winik, L.W., “When You Should Consider a Genetic Test,” Parade Magazine, Apr. 19, 1998, at 8–9.Google Scholar
See Hudson, K.L., “Genetic Discrimination and Health Insurance: An Urgent Need for Reform,” Science, 270 (1995): 391–93; Karjala, D., “A Legal Research Agenda for the Human Genome Initiative,” Jurimetrics, 32 (1992: 121–311; and Annas, G.J., “Privacy Rules for DNA Databanks. Protecting Coded ‘Future Diaries’,” JAMA, 270 (1993): 2346–50.Google Scholar
See Pokorski, supra note 11; Stone, D.A., “The Implications of the Human Genome Project for Access to Health Insurance,” in Murray, T.H. Rothstein, M.A. Murray, R.F., eds., The Human Genome Project and the Future of Health Care (Bloomington: Indiana University Press, 1996): 133–57; Murray, T.H., “Genetic Exceptionalism and ‘Future Diaries’: Is Genetic Information Different from Other Medical Information?,” in Rothstein, M.A., ed., Genetic Secrets: Protecting Privacy and Confidentiality in the Genetic Era (New Haven: Yale University Press, 1997): 60-73; Alper, J.S. Beckwith, J., “Distinguishing Genetic from Nongenetic Medical Tests: Some Implications for Antidiscrimination Legislation,” Science and Engineering Ethics, 4 (1998): 151–54; and Yesley, M.S., “Protecting Genetic Difference,” Berkeley Technology Law Journal, 13 (1998): 653–65.Google Scholar
See Preston, J., “Trenton Votes to Put Strict Limits on Use of Gene Tests by Insurers,” New York Times, June 18, 1996, at A1, B6.Google Scholar
See Lehrman, S., “Job Discrimination Based on Genetics Set for California Ban,” Nature, 393 (1998): 611.CrossRefGoogle Scholar
See generally Nelkin, D. Lindee, M.S., The DNA Mystique: The Gene as a Cultural Icon (New York: W.H. Freeman, 1995).Google Scholar
See Letter from Senator Pete Domenici, To Whom it May Concern, Re: The Genetic Confidentiality and Nondiscrimination Act of 1996 (June 17, 1996) (unpublished) (on file with authors).Google Scholar
Geller, G., “Genetic Testing for Susceptibility to Adult-Onset Cancer,” JAMA, 277 (1997): At 1468.CrossRefGoogle Scholar
See Jaroff, L., “The Gene Hunt,” Time, Mar. 20, 1989, at 67.Google Scholar
See Meschede, D., “Compound Heterozygosity for the Delta F508 and F508C Cystic Fibrosis Transmembrane Regulator (CFTR) Mutations in a Patient with Congenital Bilateral Aplasia of the Vas Deferens,” American Journal of Human Genetics, 53 (1993): 292–93; Donat, R., “The Incidence of Cystic Fibrosis Gene Mutations in Patients with Congenital Bilateral Absence of the Vas Deferens in Scotland,” British Journal of Urology, 79 (1997): 74-77; Nance, M.A., “Huntington Disease—Another Chapter Rewritten,” American Journal of Human Genetics, 59 (1996): 1-6; and Rubinsztein, D.C., “Phenotypic Characterization of Individuals with 30–40 CAG Repeats in the Huntington Disease (HD) Gene Reveals HD Cases with 36 Repeats and Apparently Normal Elderly Individuals with 36–39 Repeats,” American Journal of Human Genetics, 59 (1996): 16–22.Google Scholar
See Risch, N. Botstein, D., “A Manic Depressive History,” Nature Genetics, 12 (1996): 351–53.CrossRefGoogle Scholar
See Lehrman, supra note 20.Google Scholar